首页> 外文OA文献 >Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

【2h】

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

机译：Trastuzumab Emtansine加上HER2阳性转移性乳腺癌（Thelma）中的非聚乙二醇化脂质体DOXORUBICIN：单臂，多中心，相IB试验

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Elena López-Miranda; José Manuel Pérez-García; Serena Di Cosimo; Etienne Brain; Maja Ravnik; Santiago Escrivá-de-Romaní; Maria Vidal; Joseph Gligorov; Simona Borštnar; Laura Calabuig; Miguel Sampayo-Cordero; Andrea Malfettone; Antonio Llombart-Cussac; Thomas M. Suter; Javier Cortés;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Atezolizumab in combination with trastuzumab emtansine or with trastuzumab and pertuzumab in patients with HER2-positive breast cancer and atezolizumab with doxorubicin and cyclophosphamide in HER2-negative breast cancer: Safety and biomarker outcomes from a multi-cohort Phase Ib study [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：atezolizumab与Trastuzumab Omtansine或用曲妥珠单抗和腹腔癌患者的患者与海莫霉素和atezolizumab与海莫霉素和环磷酰胺组合，在Her2阴性乳腺癌中：来自多队阶段IB研究的安全和生物标志物结果
2. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer. [J] . Amadori D, Milandri C, Comella G, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2011,第14期

机译：非聚乙二醇脂质体阿霉素，多西紫杉醇和曲妥珠单抗作为HER-2阳性局部晚期或转移性乳腺癌的一线治疗的I / II期试验。
3. [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：[FAM-]曲妥珠单抗（T-DXD; DS-8201A）与预先接受曲妥珠单抗和紫杉烷的患者（T-DXD; DS-8201A）对受试者的ADO-TRASTUZUMAB emtansine（T-DM1）与HER2-阳性，不可切除的和/或转移性乳腺癌：阶段3 ，随机试验（Destiny-Breast03）
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm Multicenter Phase Ib Trial [O] . Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo, 2020

机译：Trastuzumab Emtansine加上HER2阳性转移性乳腺癌（Thelma）中的非聚乙二醇化脂质体DOXORUBICIN：单臂多中心相IB试验
7. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial [O] . Joaquín Gavilá, Mafalda Oliveira, Tomás Pascual, 2019

机译：Neoadjuvant非聚乙二醇化脂质体Doxorubicin，紫杉醇，曲妥珠单抗和Hertuzumab中的安全性，活动和分子异质性（Opti-Her Heart）：开放标签，单组，多中心，第2期试验

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial

著录项

引文网络

相似文献

相关主题

期刊订阅